Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

[1]  N. Izumi,et al.  Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  K. Hayashi,et al.  Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma , 2015, PloS one.

[3]  A. Gemma,et al.  A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance , 2015, Japanese journal of clinical oncology.

[4]  O. Yokosuka,et al.  Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors , 2015, Investigational New Drugs.

[5]  J. Marrero,et al.  P0372 : Gideon: A retrospective analysis of prognostic factors for survival , 2015 .

[6]  S. Morita,et al.  Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  M. Kudo.  Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan , 2015, Liver Cancer.

[8]  S. Ye,et al.  Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[10]  N. Izumi,et al.  Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. , 2014, International journal of oncology.

[11]  J. Bruix,et al.  Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. , 2014, Journal of hepatology.

[12]  N. Izumi,et al.  Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan , 2014, Journal of Cancer.

[13]  L. Jeng,et al.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[16]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[17]  C. Porta,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.

[18]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. , 2012, European journal of cancer.

[19]  M. Kudo,et al.  Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[20]  M. Lacouture,et al.  Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Colombo,et al.  Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[24]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[25]  J. Furuse,et al.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma , 2007, Cancer science.

[26]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[27]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[28]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[29]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[30]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[31]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[32]  J. Dufour,et al.  Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.

[33]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[34]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[36]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[37]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[38]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.